Article

 

S-nitrosocaptopril nanoparticles as nitric oxide-liberating and transnitrosylating anti-infective technology Public Deposited

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/articles/7w62fb24t

This is an author's peer-reviewed final manuscript, as accepted by the publisher. The published article is copyrighted by Elsevier and can be found at:  http://www.journals.elsevier.com/nanomedicine-nanotechnology-biology-and-medicine

Descriptions

Attribute NameValues
Creator
Abstract
  • Nitric oxide (NO) is an essential agent of the innate immune system which exhibits multi-mechanistic antimicrobial activity. Previously, increased antimicrobial activity against E. coli with nitric oxide releasing nanoparticles (NO-np) was demonstrated when combined with glutathione, versus NO-np alone, due to formation of S-nitrosoglutathione (GSNO), a potent transnitrosylating agent. To capitalize on this finding, the thiol-containing ACE-inhibitor, captopril, was incorporated into the NO-np system to form SNO-CAP-nps, nanoparticles that can both release NO as well as form S-nitrosocaptopril. SNO-CAP-nps demonstrated sustained release of NO and GSNO production in the presence of GSH over time. Both E. coli and MRSA were highly susceptible to SNO-CAP-np in a dose-dependent fashion, with E. coli being highly sensitive, while demonstrating no toxicity when exposed to zebrafish embryos. Given the significance of E. coli in urosepsis, as well as the ability of nanotechnology to overcome biofilm formation, SNO-CAP-np may prove useful against catheter-associated urinary tract infection.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Mordorski, B., Pelgrift, R., Adler, B., Krausz, A., da Costa Neto, A. B., Liang, H., & Friedman, A. J. (2015). S-nitrosocaptopril nanoparticles as nitric oxide-liberating and transnitrosylating anti-infective technology. Nanomedicine: Nanotechnology, Biology and Medicine, 11(2), 283-291. doi:10.1016/j.nano.2014.09.017
Journal Title
Journal Volume
  • 11
Journal Issue/Number
  • 2
Keyword
Rights Statement
Funding Statement (additional comments about funding)
  • SLH acknowledges NIH grants ES017552-01A2, ES016896-01, P30 ES03850, T32 ES0007060, and AFRL FA8650-05-1-5041. JDN acknowledges National Institutes of Health/National Institute of Allergy and Infectious Diseases grant 1RC2A1087612-01. AJF acknowledges Dermatology Foundation Career Development Award and Janssen Biotech Research Grant.
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Approved for entry into archive by Deanne Bruner(deanne.bruner@oregonstate.edu) on 2016-06-29T23:19:54Z (GMT) No. of bitstreams: 2 bryan.harper@oregonstate.edu545327523.zip: 138723 bytes, checksum: 687aa68328bf684206adb4545a03431d (MD5) SNO-CAP paper - submitted.docx: 142252 bytes, checksum: 7a1f930136cf6e460824101c5a74690c (MD5)
  • description.provenance : Submitted by Open Access (openaccess@library.oregonstate.edu) on 2016-06-29T17:41:37Z No. of bitstreams: 1 SNO-CAP paper - submitted.docx: 142252 bytes, checksum: 7a1f930136cf6e460824101c5a74690c (MD5)
  • description.provenance : Made available in DSpace on 2016-06-29T23:19:54Z (GMT). No. of bitstreams: 2 bryan.harper@oregonstate.edu545327523.zip: 138723 bytes, checksum: 687aa68328bf684206adb4545a03431d (MD5) SNO-CAP paper - submitted.docx: 142252 bytes, checksum: 7a1f930136cf6e460824101c5a74690c (MD5) Previous issue date: 2015-02
  • description.peerreviewnotes : Mordorski, B., Pelgrift, R., Adler, B., Krausz, A., da Costa Neto, A. B., Liang, H., & Friedman, A. J. (2015). S-nitrosocaptopril nanoparticles as nitric oxide-liberating and transnitrosylating anti-infective technology. Nanomedicine: Nanotechnology, Biology and Medicine, 11(2), 283-291. doi:10.1016/j.nano.2014.09.017

Relationships

Parents:

This work has no parents.

Items